Sobi's $75 Million Upfront Buys Innate Pharma Time Until 2028
Innate Pharma closed its lacutamab deal with Sobi, triggering a $75 million upfront payment and a funding runway into Q1 2028 despite a €19.6 million first-half net loss.
Topic
Partnership
Topic
Partnership
Tabi Connect and Kleinschmidt Automate Freight Quoting
Tabi Connect and Kleinschmidt will automate freight quoting via the Kleinschmidt Intelligence Network, applying broker pricing ru…
Beyond Limits and Collaborative Franchise Systems Launch Franchise Coaching Platform
Beyond Limits has teamed with Collaborative Franchise Systems to deliver what the companies call a first-of-its-kind AI-driven fr…
POLITICO Named Official Media Partner of U.S. Chamber's B20 USA Summit
POLITICO will be official media partner for the B20 USA Summit, the first U.S. edition of the Business 20, running November 9-11,…